Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 05, 2018 16:01 ET | Source: VBL Therapeutics

VBL Therapeutics Presents Positive Data on its MOSPD2 Platform Technology in Oncology and Inflammation at BIO 2018

TEL AVIV, Israel, June 05, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) today presented data on its novel MOSPD2 program in oncology and inflammation at the 2018 BIO International...
May 24, 2018 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Present at Upcoming Conferences in June

TEL AVIV, Israel, May 24, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
May 17, 2018 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics Announces First Quarter 2018 Financial Results

Conference Call and Webcast at 8:30am Eastern Time Today TEL AVIV, Israel, May 17, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the...
May 07, 2018 09:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Present Data on its MOSPD2 Oncology Program at MIXiii-BIOMED 2018 on May 15

TEL AVIV, Israel, May 07, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
May 01, 2018 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Report First Quarter 2018 Financial Results on May 17

TEL AVIV, Israel, May 01, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
April 16, 2018 09:00 ET | Source: VBL Therapeutics

VBL Therapeutics Presents Late Breaking Research Demonstrating Immune-cell Mediated Killing of Cancer Cells by a Novel Bi-specific Antibody at AACR

TEL AVIV, Israel, April 16, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) today presented a late-breaking study demonstrating a novel bi-specific antibody that induces immune-cell mediated...
April 10, 2018 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Present Late-Breaking Research at the American Association for Cancer Research (AACR) 2018 Annual Meeting on April 16

TEL AVIV, Israel, April 10, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
April 09, 2018 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics Awarded $2.5 Million Non-Dilutive Grant by the Israel Innovation Authority

TEL AVIV, Israel, April 09, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announced that it has been awarded a grant of 8.9 million New Israeli Shekels (approximately $2.5 million)...
March 15, 2018 07:15 ET | Source: VBL Therapeutics

VBL Therapeutics Announces Year End 2017 Financial Results

Conference Call and Webcast at 8:30am Eastern Time TEL AVIV, Israel, March 15, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the...
March 09, 2018 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Report Fiscal 2017 Results on March 15

TEL AVIV, Israel, March 09, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...